Welcome to CDC Stacks | Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C - 39194 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C
  • Published Date:
    Mar 29 2016
  • Publisher's site:
  • Source:
    Int J Circumpolar Health. 2016; 75.
Filetype[PDF - 319.82 KB]


Details:
  • Pubmed ID:
    27029671
  • Pubmed Central ID:
    PMC4814572
  • Funding:
    U01 PS001097/PS/NCHHSTP CDC HHS/United States
    U01 PS004113/PS/NCHHSTP CDC HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Background

    There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations.

    Objective

    To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI) population.

    Design

    In an outcomes study of 1,379 AN/AI persons with chronic HCV infection from 1995 through 2013, we examined treatment results of 189 persons treated with standard interferon, interferon plus ribavirin, pegylated interferon plus ribavirin and triple therapy with a protease inhibitor. For individuals treated with pegylated interferon and ribavirin, the effect of patient characteristics on response was also examined.

    Results

    Sustained virologic response (SVR) with standard interferon was 16.7% (3/18) and with standard interferon and ribavirin was 29.7% (11/37). Of 119 persons treated with pegylated interferon and ribavirin, 61 achieved SVR (51.3%), including 10 of 46 with genotype 1 (21.7%), 38 of 51 with genotype 2 (74.5%) and 13 of 22 with genotype 3 (59.1%). By multivariate analysis, SVR in the pegylated interferon group was associated with female sex (p=0.002), estimated duration of infection (p=0.034) and HCV genotype (p<0.0001). There was a high discontinuation rate due to side effects in those treated with pegylated interferon and ribavirin for genotype 1 (52.2%). Seven of 15 genotype 1 patients treated with pegylated interferon, ribavirin and telaprevir or boceprevir achieved SVR (46.7%).

    Conclusions

    We had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3. However, there were low SVR and high discontinuation rates for those with genotype 1.